Clinical trials: IgAN
IgA Nephropathy
Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
Immunoglobulin A (IgA) nephropathy is the common type of primary glomerulonephritis in the world. A wealth of literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular…
- Trial name
- NCT00599963
- Testing
- paricalcitol
- Where
- Hong Kong
- Sponsor
- Chinese University of Hong Kong
IgA Nephropathy
BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration
The purpose of this study is to evaluate the efficacy and safety of subcutaneous blisibimod administration in addition to standard therapy in patients with biopsy proven IgA Nephropathy with persistent proteinuria of between 1-6…
- Trial name
- NCT02062684
- Testing
- Blisibimod
- Where
- 23 sites in Czechia, Germany and 8 more
- Volunteers
- 57 people
- Sponsor
- Anthera Pharmaceuticals
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07305116
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Kidney Disease, Glomerulonephritis
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
This study will have two parts. The main aims are to: check the side effects from mezagitamab. check for long-term side effects from mezagitamab.
- Trial name
- NCT05174221
- Testing
- Mezagitamab
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 17 people
- Sponsor
- Takeda
Progressive IgA Nephropathy, Proteinuria
Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in…
- Trial name
- NCT02282930
- Testing
- ACTH (Acthar) Gel
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Immunoglobulin A Nephropathy (IgAN)
A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with IgAN.
- Trial name
- NCT07135219
- Testing
- Biological: cizutamig
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking University First Hospital
IgA Nephropathy
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
The investigators are registering all biopsy-proven primary IgA nephropathy (IgAN) patients at recruited hospitals and developing a IgAN database in China.
- Trial name
- NCT03001947
- Testing
- No intervention
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Sun Yat-sen University
Immunoglobulin A Nephropathy
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
- Trial name
- NCT06952426
- Testing
- No intervention, Other treatment, Iptacopan
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy
A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.
- Trial name
- NCT00793585
- Testing
- allopurinol, continue their usual therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
IgA Nephropathy
A Phase IIa Study in Primary IgA Nephropathy Patients
This is a phase IIa, multicenter, single-arm, open-label study to evaluate the safety and efficacy of XH-S003 in patients with primary IgA nephropathy
- Trial name
- NCT07634744
- Testing
- XH-S003 Capsule
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Primary IgA Nephropathy
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy at risk of progressing to end-stage renal disease(ESRD), despite maximum tolerated treatment with…
- Trial name
- NCT05799287
- Testing
- Telitacicept
- Where
- 101 sites in China
- Volunteers
- 318 people
- Sponsor
- RemeGen Co., Ltd.
Primary IgA Nephropathy
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials.
- Trial name
- NCT04557462
- Testing
- LNP023
- Where
- 161 sites in United States, Argentina and 34 more
- Volunteers
- 540 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Diseases, Chronic, Glomerular Diseases
Model Development and Application Based on Renal Pathology Images
This single-center retrospective observational cohort study will utilize digital renal pathology images along with corresponding clinical and laboratory data from patients who underwent kidney biopsy at Union Hospital, Tongji…
- Conditions
- Kidney Diseases, Chronic, Glomerular Diseases, Tubulointerstitial Kidney Diseases, IgA Nephropathy (IgAN)
- Trial name
- NCT07816874
- Where
- China
- Volunteers
- 8,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Glomerulonephritis
Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor
To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy.
- Trial name
- NCT00437463
- Testing
- Ramipril
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Sanofi
IgAN
FXS6837 for the Treatment of IgAN Patients
This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of FXS6837 capsules in IgAN patients.
- Trial name
- NCT07502638
- Testing
- FXS6837 Dose 1, FXS6837 Dose 2
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
ANCA Associated Vasculitis, Extramembranous Glomerulopathy
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.
- Conditions
- ANCA Associated Vasculitis, Extramembranous Glomerulopathy, Nephrotic Syndrome, Minimal Change, Interstitial Nephritis
- Trial name
- PROTECT-Fi (NCT07010250)
- Where
- France
- Volunteers
- 146 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
IgA Nephropathy
Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers
This study will help to show the efficacy of vitamin D and address the optimal strategy to minimize renal injury in IgAN patients.
- Trial name
- NCT01237028
- Testing
- Calcitriol
- Where
- 7 sites in South Korea
- Volunteers
- 168 people
- Sponsor
- Yonsei University
Tonsillectomy
Tonsillectomy and Primitive IgA Nephropathy in Children: Strasbourg Cohort and Assessment Practices in Inter North East Region
Primitive kidney disease IgA, represented by Berger's disease and rheumatoid purpura nephropathy, are the first cause of kidney failure from chronic glomerulonephritis: changes in 20 years to end-stage renal failure is described…
- Trial name
- NCT02829164
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Strasbourg, France
Treatment Resistant Nephrotic Syndrome
Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)
This study will examine the safety and effectiveness of ACTHAR Gel, when used to treat 15 patients diagnosed with "treatment resistant nephrotic syndrome." Nephrotic syndrome is a group of symptoms that includes low levels of…
- Trial name
- NCT01129284
- Testing
- ACTHAR gel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
QLS7305 injection is a chemically synthesized double-stranded small interfering RNA (siRNA) targeting complement C3, covalently linked to a ligand containing N-acetylgalactosamine (GalNAc) residues.
- Conditions
- IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G), Primary Membranous Nephropathy
- Trial name
- NCT07730632
- Testing
- QLS7305 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.